Glox Therapeutics Awarded Share of £3M Collaborative Discovery Programme Funding from Cystic Fibrosis Antimicrobial Resistance Syndicate

Glox Therapeutics will receive up to £500,000 of the fund to accelerate the development of its novel precision antibiotics, helping to address the growing need for effective treatments to overcome antimicrobial-resistant lung infections in people with cystic fibrosis.